<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032560</url>
  </required_header>
  <id_info>
    <org_study_id>ABX464-921</org_study_id>
    <nct_id>NCT05032560</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study in Healthy Japanese Volunteers</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of ABX464 Capsules in Healthy Japanese Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abivax S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abivax S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study consists of Part A, a randomized double-blind, single-ascending-dose study, and&#xD;
      Part B, a randomized, double-blind, semi-sequential, escalating multiple-dose study, in&#xD;
      healthy Japanese volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A includes the following two dose regimen groups:&#xD;
&#xD;
        -  25 mg dose regimen group: ABX464 25 mg or placebo&#xD;
&#xD;
        -  50 mg dose regimen group: ABX464 50 mg or placebo In each dose regimen group, 12&#xD;
           subjects will be randomly assigned, according to a 3:1 ratio, to receive either ABX464&#xD;
           (9 subjects) or its matching placebo (3 subjects).&#xD;
&#xD;
      Part B includes the following two dose regimen groups:&#xD;
&#xD;
        -  25 mg dose regimen group: ABX464 25 mg or placebo for 28 days&#xD;
&#xD;
        -  50 mg dose regimen group: ABX464 50 mg or placebo for 28 days&#xD;
&#xD;
      In each dose regimen group, 12 subjects will be randomly assigned, according to a 3:1 ratio,&#xD;
      to receive either ABX464 (9 subjects) or its matching placebo (3 subjects).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A: single-ascending-dose Part B: escalating multiple-dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and SAEs</measure>
    <time_frame>6 weeks</time_frame>
    <description>number of incidences of all adverse events (AEs) (causally related and non-related) and SAEs, will be described further categorized by severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of treatment-emergent serious adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>number of incidences of treatment-emergent serious adverse events will be described</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of treatment-emergent adverse events of special interest (AESIs).</measure>
    <time_frame>6 weeks</time_frame>
    <description>number of incidences of treatment-emergent adverse events of special interest (AESIs) will be described.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of clinically significant laboratory abnormalities</measure>
    <time_frame>6 weeks</time_frame>
    <description>number of incidences of clinically significant laboratory abnormalities will be described</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>42 days</time_frame>
    <description>Cmax of ABX464 will be derived from the plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>42 days</time_frame>
    <description>AUC of ABX464 will be derived from the plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration (tmax)</measure>
    <time_frame>42 days</time_frame>
    <description>Tmax of ABX464 will be derived from the plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miR124 level</measure>
    <time_frame>42 days</time_frame>
    <description>concentration of miR124 expression will be measured in blood</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>25 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive a single oral dose of ABX464 25 mg or its matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive a single oral dose of ABX464 50 mg or its matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive a daily oral dose of ABX464 25 mg or its matching placebo for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg mulptiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive a daily oral dose of ABX464 50 mg or its matching placebo for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464</intervention_name>
    <description>Drug: ABX464 ABX464 is a new anti-inflammatory drug</description>
    <arm_group_label>25 mg multiple dose</arm_group_label>
    <arm_group_label>25 mg single dose</arm_group_label>
    <arm_group_label>50 mg mulptiple dose</arm_group_label>
    <arm_group_label>50 mg single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Matching Placebo placebo matching with ABX464</description>
    <arm_group_label>25 mg multiple dose</arm_group_label>
    <arm_group_label>25 mg single dose</arm_group_label>
    <arm_group_label>50 mg mulptiple dose</arm_group_label>
    <arm_group_label>50 mg single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male Japanese volunteers.&#xD;
&#xD;
          2. 20 to 45 years old.&#xD;
&#xD;
          3. Considered by the Investigator, as healthy based on history, physical examination, and&#xD;
             complete laboratory evaluation (laboratory parameters should be within normal ranges&#xD;
             of the study center's laboratory or considered not clinically significant by the&#xD;
             Investigator).&#xD;
&#xD;
          4. Vital signs (supine blood pressure, resting pulse rate, body temperature) should be&#xD;
             within normal ranges and no deviation from standard 12-lead electrocardiogram (ECG)&#xD;
             should be observed at screening.&#xD;
&#xD;
             Body mass index (BMI) should be between 18 (inclusive) and 27 kg/mÂ² (inclusive).&#xD;
&#xD;
          5. Non-smokers at enrolment.&#xD;
&#xD;
          6. Subjects must understand, sign and date the written voluntary Informed Consent Form at&#xD;
             the visit prior to any protocol-specific procedures.&#xD;
&#xD;
          7. Able and willing to comply with study visits and procedures as per protocol.&#xD;
&#xD;
          8. Males receiving the study treatment and their partners must agree to use a highly&#xD;
             effective contraceptive method during the study and for 6 months after the last dose&#xD;
             of study drug. Highly effective methods of contraception include true abstinence,&#xD;
             intrauterine device (IUD) or hormonal contraception aiming at inhibition of ovulation,&#xD;
             intrauterine hormone releasing system, bilateral tubal ligation, and vasectomized&#xD;
             partner. True abstinence is defined when this is in line with the preferred and usual&#xD;
             lifestyle of the subject. In each case of delayed menstrual period (over 1 month&#xD;
             between menstruations) in a female partner of a male subject, confirmation of absence&#xD;
             of pregnancy of the partner is required. Male subjects must not be planning pregnancy,&#xD;
             should use a condom and must not donate sperm during the study and for 6 months after&#xD;
             the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute disease state (e.g., nausea, vomiting, diarrhea, or fever within a week) or&#xD;
             chronic infectious disease (positive results for hepatitis B surface antigen [HBsAg],&#xD;
             hepatitis C virus antibody, human immunodeficiency virus antigen/antibody,&#xD;
             tuberculosis determined by QuantiFERON-TB Gold Plus test). Subjects who have positive&#xD;
             hepatitis B core antibody [HBcAb] can be enrolled but must have an undetectable&#xD;
             hepatitis B virus [HBV] viral load (HBV DNA test).&#xD;
&#xD;
          2. Positive results for SARS-CoV-2 antigen determined by polymerase chain reaction&#xD;
             method.&#xD;
&#xD;
          3. History of recent grade 3 or 4 opportunistic infection or underlying conditions that&#xD;
             may predispose them to grade 3 or grade 4 infection.&#xD;
&#xD;
          4. History of cardiovascular, pulmonary, gastrointestinal, hepatic, pancreatic, renal,&#xD;
             metabolic, hematological, neurological, psychiatric, or systemic disease that could&#xD;
             jeopardize the safety of the subject or the validity of the study results.&#xD;
&#xD;
          5. Illicit drug or alcohol abuse, or dependence within a year.&#xD;
&#xD;
          6. Blood donation within 3 months prior to screening.&#xD;
&#xD;
          7. Use of any investigational or non-registered product within 3 months or within 5&#xD;
             half-lives preceding baseline, whichever is longer.&#xD;
&#xD;
          8. Use of any immunosuppressive drugs (except topical steroids) within 3 months prior to&#xD;
             first dose.&#xD;
&#xD;
          9. Any history of hypersensitivity to drugs.&#xD;
&#xD;
         10. Any condition, which in the opinion of the Investigator, could compromise the&#xD;
             subject's safety or adherence to the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Gineste, PharmD</last_name>
    <phone>+33 1 5383 0961</phone>
    <email>paul.gineste@abivax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie Biguenet, MD</last_name>
    <phone>+33 1 5383 0961</phone>
    <email>sophie.biguenet@abivax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuko Owada, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

